Core Viewpoint - The A-share market has shown strong performance, with major indices experiencing significant increases, which has positively impacted fund performance. As of August 20, 2025, multiple products under Xinda Australia Fund have reported outstanding returns, with 41 products achieving over 30% returns in the past year, showcasing the company's robust investment capabilities [1][4]. Group 1: Fund Performance - As of August 20, 2025, 41 products from Xinda Australia Fund have achieved returns exceeding 30% in the past year, with 34 products rising over 50% and 25 products increasing over 70%. Notably, 6 products have doubled in value [1]. - The top-performing funds include Xinda Performance Driven A with a return of 149.64%, Xinda Star Yi A at 118.55%, and Xinda Bojian Growth One-Year Open A at 117.29% [2][4]. Group 2: Investment Strategy - The strong performance of Xinda Australia Fund's products is primarily driven by actively managed equity funds, which have become the core engine of performance growth, demonstrating the company's investment strength in active equity [4]. - The company employs a diversified research matrix covering key sectors such as manufacturing, technology, consumption, and new energy, optimizing its investment research team to enhance its investment capabilities [5]. Group 3: Quantitative and Pension Strategies - Xinda Australia Fund's active equity is considered the "alpha engine," with quantitative investments capturing market beta effectively. The company utilizes a "HI+AI" dual-engine approach to develop a range of quantitative products [7]. - In the pension finance sector, the company focuses on "target date strategies" to assist investors in achieving comprehensive retirement planning, with a notable return of 31.04% for the Xinda Yiyuan Pension Target 2055 Five-Year Holding A product [7]. Group 4: Future Outlook - Looking ahead, Xinda Australia Fund aims to continue prioritizing the interests of its investors, deepening its commitment to long-term value investment, optimizing its research system, and expanding its product line to create sustainable returns for investors [8].

| | 基本信息 | | 收益评价 | | 基本信息 | | 收益评价 | | --- | --- | --- | --- | --- | --- | --- | --- | | 基金代码 | 基金简称 | 风险等级 | 最近一年 | 基金代码 | 基金简称 | 风险等级 | 最近一年 | | | | | 排名 | | | | 排名 | | 016810 | 信澳博见成长一年定开A | R3中国际 | 6/3751 | 019031 | 信澳医药健康A | R3中风险 | 338/3751 | | 011188 | 信澳星奕A | B3中国际 | 12/3751 | 011598 | 信溃量化多因子A(LOF) | R3中风险 | 518/3751 | | 012079 | 信澳新能源精选A | R4中高风险 | 38/3751 | 166107 | 信澳成长精选A | B3中国版 | 540/3751 | | 610001 | 信澳领先增长A | R3中风险 | 51/3751 | 166108 | 信澳转型创新A | R4中高风险 | 159/899 | | 020303 | 信澳星亮智选A | R3中国 ...